N maiwei-u landed on the science and innovation board today, and the A-share innovative medicine board added “elite soldiers”, but it broke at the opening, and the call auction fell 8.05%. Then it was depressed all the way to the closing, down nearly 30%. According to the 500 shares signed on the science and innovation board, the first contract lost about 5000 yuan.
the “inner roll” era of innovative drugs, with high R & D investment
The prospectus shows that Maiwei biology is an innovative biopharmaceutical enterprise, and its main products are antibody drugs. It is worth noting that company has not yet commercialized its products and generated operating revenue, but its R & D expenses are high. the company currently holds 15 varieties under research, of which 3 varieties have submitted listing applications. Among them, the closest product to commercialization is 9mw0113, which is expected to be licensed in the first quarter of 2022.
9mw0113 is a biological analogue of adalimumab. Guotai Junan Securities Co.Ltd(601211) suggests that the market penetration of adalimumab in China is expected to increase rapidly, and the market scale is expected to reach 24.011 billion yuan in 2030. However, 9mw0113 is TNF- ɑ The competition of target drugs is very fierce. At present, there are five drugs of the same type in the market. Industry insiders believe that Maiwei biological TNF- ɑ After the target drugs are listed, the selling price may be squeezed by market competition, and the profit may be limited.
innovative drugs break into normal?
Pharmaceutical R & D enterprises need a lot of capital investment. The listing of Maiwei biology adopts the fifth set of listing standards set by Kechuang board for unprofitable biomedical companies.
Maiwei biology is the 13th biomedical enterprise to adopt the fifth set of standards. Most of the previously listed companies are still not profitable. Since the listing, the performance has been poor. Today, driven by Maiwei biology, “green” has been.
Recently listed Dizhe pharmaceutical-u and Yahong pharmaceutical-u have the same “no revenue and no product listing”, which broke on the first day of trading. Among them, a total of 148000 shares of Dizhe pharmaceutical-u, which had the largest decline on the first day, were abandoned before landing on the science and innovation board, with an issue price of 52.58 yuan. On the first day, it fell by more than 20% compared with the issue price, and so far it has been depressed by nearly 30%.
since the beginning of 2021, many innovative pharmaceutical enterprises have landed in the capital market, and the decline list of new shares on the first day has almost been “contracted” by innovative pharmaceutical enterprises, in addition to the above stocks, Baiji shenzhou-u, Liaoning Chengda Biotechnology Co.Ltd(688739) and Nanmo biology have also broken one after another
organization: the cost performance of innovative drugs in shock
According to the data, as of December 2021, the number of new drug projects applying for listing for the first time reached 198, exceeding that of the whole year of 2020. The number of new drugs on the market reached 97, a record high. According to the number of declared projects, Southwest Securities Co.Ltd(600369) it is expected that the number of new drugs on the market in 2022 is expected to see a greater increase. China’s new drug market is about to usher in a blowout period.
Southwest Securities Co.Ltd(600369) said that after the preparation in previous years, China’s innovative drugs have reached a new wave of centralized listing period. It is expected that the number of innovative drugs listed in China will reach a record high in the next two years, and Chinese innovative drug enterprises have reached the harvest period one after another. After the correction and shock in 2021, most of the innovative drug targets of A-Shares and Hong Kong stocks have good cost performance.
